A man from the world’s largest known Alzheimer’s family should have lost his memory by his late 40s. Every other carrier of ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Scientists have shown that boosting the protein Sox9 in astrocytes can activate a receptor called MEGF10, enabling these brain support cells to engulf and clear existing amyloid plaques in Alzheimer’s ...

Scientists have discovered a way to activate a built-in brain cleanup system that may help counter Alzheimer’s disease. By ...

STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...

Scientists have discovered a way to help the brain clean itself of harmful Alzheimer’s plaques by activating its own support cells. By increasing a protein called Sox9, researchers were able to boost ...

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

First trial of concurrent amyloid and tau immunotherapies in sporadic Alzheimer’s is underway. Safety data are a go for subcutaneous remternetug. Plaque removal correlates with cognitive benefit in ...

Reduced amyloid burden after treatment with the antiamyloid donanemab (Kisunla, Eli Lilly) correlated strongly with slower cognitive and functional decline in adults with early symptomatic Alzheimer’s ...